Healthcare Services

Global Tuberculosis Therapeutics Industry Trends and Market Growth Forecast for 2026–2030

April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Tuberculosis Therapeutics Market Over The 2026–2030 Period?

The tuberculosis therapeutics market has experienced substantial growth in recent years. This market is projected to expand from $2 billion in 2025 to $2.13 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 6.3%. Historically, this growth can be attributed to factors such as the global burden of TB disease, the extensive application of first-line TB medications, the expansion of government-led TB control programs, the accessibility of generic TB drugs, and international financial backing for TB initiatives.

The tuberculosis therapeutics market is projected to experience significant expansion over the next few years, with its size expected to reach $2.7 billion by 2030, advancing at a compound annual growth rate (CAGR) of 6.1%. This anticipated growth during the forecast period is primarily driven by the increasing prevalence of multidrug-resistant TB, continuous advancements in the creation of novel TB drugs, a rise in global health funding, the broader implementation of digital adherence technologies, and an escalating focus on preventive TB treatment strategies. Prominent trends within this forecast period include the accelerated development of therapies for drug-resistant TB, the increasing adoption of combination treatment regimens, a growing emphasis on achieving shorter treatment durations, the expansion of public health TB programs, and improvements in patient adherence monitoring.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20983&type=smp

Which Major Factors Are Driving The Expansion Of The Tuberculosis Therapeutics Market?

The anticipated expansion of the tuberculosis therapeutics market is attributed to the increasing co-infection rates of tuberculosis (TB) and human immunodeficiency virus (HIV). TB-HIV co-infection rates describe the frequency of people simultaneously affected by both diseases, a situation that complicates diagnosis, therapy, and patient prognoses because of immune system suppression and concurrent epidemics. This rise in co-infections fuels the necessity for integrated therapeutic strategies designed to treat TB infection in HIV-positive individuals, thereby enhancing overall health results and alleviating the strain of both conditions. For example, data from March 2024 published by the Centers for Disease Control and Prevention, a US-based government agency, indicated a rise in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Consequently, the growing rates of TB-HIV co-infection are propelling the expansion of the tuberculosis therapeutics market.

How Is The Tuberculosis Therapeutics Market Segmented Across Key Categories?

The tuberculosis therapeutics market covered in this report is segmented –

1) By Type: Active Tuberculosis (TB), Latent Tuberculosis (TB)

2) By Drug Type: Isoniazid, Rifampin, Pyrazinamide, Hydrazine derivatives, Miscellaneous anti-tubercular drugs, Ethambutol

3) By Route of Administration: Oral, Parenteral, Other route of administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol), Second-Line Drugs (Fluoroquinolones, Aminoglycosides), Combination Therapies, Drug-Resistant TB Treatments (MDR-TB, XDR-TB)

2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis, Rifampicin-Based Regimens, Rifapentine-Based Regimens, Combination Prophylactic Therapies

What Key Trends Are Influencing The Development Of The Tuberculosis Therapeutics Market?

Leading enterprises within the tuberculosis therapeutics market are actively pursuing the creation of novel solutions, prominently featuring combination therapy, with the goal of enhancing treatment effectiveness, shortening therapy duration, and combating drug-resistant tuberculosis strains. This approach involves employing multiple medications from distinct categories to address a disease, thereby seeking to boost treatment efficacy, mitigate resistance, and achieve superior patient results. A notable example occurred in July 2024, when Johnson & Johnson, a US-based pharmaceutical company, reached a significant achievement in tuberculosis treatment through the approval of SIRTURO (bedaquiline) by both the U.S. FDA and the European Commission. This groundbreaking medication represents the first in more than four decades specifically engineered to combat multidrug-resistant tuberculosis (MDR-TB). Its distinctive mode of action involves inhibiting the ATP synthase enzyme, which is vital for the energy production of TB bacteria, thus providing a precise and potent therapeutic strategy. Integrating SIRTURO into combination therapies significantly boosts the overall effectiveness of MDR-TB regimens, leading to shorter treatment periods and enhanced patient adherence.

Who Are The Dominant Players Shaping The Tuberculosis Therapeutics Market Landscape?

Major companies operating in the tuberculosis therapeutics market are Pfizer Inc, Johnson & Johnson, Roche Holding AG, Merck & Co. Inc, Sanofi S.A, Novartis AG, GlaxoSmithKline plc, Viatris Inc, Cipla Limited, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Sequella Inc, AstraZeneca plc, Eli Lilly and Company, Biofabri S L, LegoChem Biosciences, BioVersys AG, SENTAN Pharma Inc, ViChem Pharmaceuticals Inc, PDS Biotechnology Corporation, BioNTech SE, Qurient Co Ltd

Read the full tuberculosis therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/tuberculosis-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The Tuberculosis Therapeutics Market?

North America was the largest region in the tuberculosis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tuberculosis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Tuberculosis Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20983&type=smp

Browse Through More Reports Similar to the Global Tuberculosis Therapeutics Market 2026, By The Business Research Company

Hepatitis Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Anti Infective Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-global-market-report

Therapeutic Bcg Vaccines Global Market Report

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795